Rocket


Overview
Financials
News + Filings
Key Docs
Ownership
Insiders


All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Quarterly results
Kymera Therapeutics, Inc. Create: Alert

All | News | Filings
Date FiledTypeDescription
08/03/2023 10-Q Quarterly Report for the period ended June 30, 2023
08/03/2023 8-K Quarterly results
Docs: "Kymera Therapeutics Announces Second Quarter 2023 Financial Results and Provides a Business Update KT-474/SAR444656 Phase 2 trials for both hidradenitis suppurativa and atopic dermatitis planned to start in 4Q23 by partner Sanofi Phase 1 oncology trials for KT-253 , KT-333 , and KT-413 degraders ongoing, with clinical updates planned for later in 2023 June 30, 2023 cash balance approximately $472 million, with cash runway into second half of 2025 Company to hold quarterly results call and webcast at 8:30 a.m. ET"
06/16/2023 8-K Submission of Matters to a Vote of Security Holders  Interactive Data
Docs: "UNITED STATES SECURITIES AND EXCHANGE COMMISSION"
05/04/2023 10-Q Quarterly Report for the period ended March 31, 2023
05/04/2023 8-K Quarterly results
04/27/2023 DEFA14A Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material:
04/27/2023 DEF 14A Form DEF 14A - Other definitive proxy statements:
03/10/2023 8-K Regulation FD Disclosure  Interactive Data
Docs: "UNITED STATES SECURITIES AND EXCHANGE COMMISSION"
02/27/2023 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
Docs: "UNITED STATES SECURITIES AND EXCHANGE COMMISSION"
02/23/2023 S-8 Form S-8 - Securities to be offered to employees in employee benefit plans:
02/23/2023 10-K Annual Report for the period ended December 31, 2022
02/23/2023 8-K Quarterly results
Docs: "Kymera Therapeutics Announces Fourth Quarter and Full Year 2022 Financial Results and Provides a Business Update Partner Sanofi plans to initiate Phase 2 trial of IRAK4 degrader KT-474 in 2023 Phase 1 trials for STAT3 and IRAKIMiD degraders ongoing, with data evaluating clinical activity expected to be shared in 2023 Phase 1 clinical trial for MDM2 degrader expected to be initiated in early 2023 Year-end 2022 cash balance of approximately $560 million with cash runway into second half of 2025 Company to hold quarterly results call at 8:30 a.m. ET"
02/14/2023 SC 13G BAKER BROS. ADVISORS LP reports a 5.2% stake in Kymera Therapeutics, Inc.
02/14/2023 SC 13G/A PRICE T ROWE ASSOCIATES INC reports a 8% stake in KYMERA THERAPEUTICS INC
02/14/2023 SC 13G Form SC 13G - Statement of acquisition of beneficial ownership by individuals:
02/08/2023 SC 13G Form SC 13G - Statement of acquisition of beneficial ownership by individuals:
02/06/2023 SC 13G/A Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]
02/01/2023 SC 13G/A Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]
01/10/2023 8-K Results of Operations and Financial Condition, Financial Statements and Exhibits  Interactive Data
Docs: "UNITED STATES SECURITIES AND EXCHANGE COMMISSION",
"Kymera Therapeutics Shares Key 2023 Goals to Support its Evolution into a Fully Integrated Degrader Medicines Company"
12/14/2022 8-K Regulation FD Disclosure, Financial Statements and Exhibits  Interactive Data
Docs: "Kymera Therapeutics, Inc. Corporate Presentation, furnished herewith"
12/14/2022 8-K Regulation FD Disclosure, Other Events, Financial Statements and Exhibits  Interactive Data
Docs: "Kymera Announces Positive Results from Phase 1 Clinical Trial Evaluating KT-474 in Patients with HS and AD and Sanofi's Decision to Advance KT-474 into Phase 2 Clinical Trials"
11/03/2022 10-Q Quarterly Report for the period ended September 30, 2022
11/03/2022 8-K Quarterly results
10/13/2022 8-K Regulation FD Disclosure, Financial Statements and Exhibits  Interactive Data
Docs: "UNITED STATES SECURITIES AND EXCHANGE COMMISSION",
"Kymera Therapeutics to Hold Investor Webcast on December 14 to Share Clinical Data from KT-474 Phase I Patient Cohort and Oncology Pipeline"
09/06/2022 424B3 Form 424B3 - Prospectus [Rule 424(b)(3)]:
08/23/2022 SC 13D/A Form SC 13D/A - General statement of acquisition of beneficial ownership: [Amend]
08/19/2022 8-K Quarterly results
08/09/2022 10-Q Quarterly Report for the period ended June 30, 2022
08/09/2022 8-K Quarterly results
07/11/2022 SC 13G/A Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]
07/08/2022 8-K Quarterly results
06/16/2022 8-K Quarterly results
06/01/2022 SC 13D/A Form SC 13D/A - General statement of acquisition of beneficial ownership: [Amend]
05/03/2022 10-Q Quarterly Report for the period ended March 31, 2022
  Next >>

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy